每经AI快讯，11月14日，石四药集团有限公司港交所公告，本集团已取得中国国家药品监督管理局有 关吲哚布芬片(0.2g)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。吲哚布芬片主要 用于治疗动脉硬化引起的缺血性心血管病变、缺血性脑血管病变及静脉血栓形成，也可用于血液透析时 预防血栓形成。 ...

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has obtained the production registration approval for Indobufene Tablets (0.2g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1 - The Indobufene Tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The tablets can also be used to prevent thrombosis during hemodialysis [1]

石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局有關吲哚布芬片(0.2g)的藥品生產註冊批件，屬於化學 藥品第3類，視同通過一致性評價。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 吲哚布芬片主要用於治療動脈硬化引起的缺血性心血管病變、缺血性腦血管病變及靜脈血栓形 成，也可用於血液透析時預防血栓形成。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年十一月十四日 ...

Core Insights - Sichuan Kelun Pharmaceutical Co., Ltd. increased its stake in Shijiazhuang Fourth Pharmaceutical Co., Ltd. by acquiring 1,128,000 shares at an average price of HKD 3.0978 per share, totaling approximately HKD 3.4943 million [1] Group 1 - The shareholding of Sichuan Kelun Pharmaceutical increased from 22.99% to 23.03% following the acquisition [1][2] - The total number of shares held by Sichuan Kelun Pharmaceutical after the purchase is 679,558,000 [1][2]

Core Insights - Sichuan Kelun Pharmaceutical Co., Ltd. has increased its stake in Stone Four Pharmaceutical Group by acquiring 1.128 million shares at a price of HKD 3.0978 per share, totaling HKD 3.4943 million [1] - Following this acquisition, Sichuan Kelun's total shareholding in Stone Four Pharmaceutical Group has reached approximately 680 million shares, representing a 23.03% ownership stake [1]

Core Insights - Sichuan Kelun Pharmaceutical Co., Ltd. has increased its stake in Stone Four Pharmaceutical Group by acquiring 1.128 million shares at a price of HKD 3.0978 per share, totaling HKD 3.4943 million [1] - Following this acquisition, Sichuan Kelun's total shareholding in Stone Four Pharmaceutical Group has reached approximately 680 million shares, representing a 23.03% ownership stake [1]

Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has received approval from the National Medical Products Administration of China for its injectable Lincomycin Hydrochloride (2ml:0.6g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Lincomycin Hydrochloride is primarily used for patients who are unsuitable for penicillin, treating severe infections caused by sensitive strains such as Streptococcus, Pneumococcus, and Staphylococcus [1]

Core Viewpoint - The company, Shijiazhuang Fourth Pharmaceutical Group, has received approval from the National Medical Products Administration of China for its injectable Lincomycin Hydrochloride solution (2ml:0.6g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Lincomycin Hydrochloride solution is primarily used for patients who cannot use penicillin, treating severe infections caused by sensitive strains such as Streptococcus, Pneumococcus, and Staphylococcus [1]

Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Lincomycin Hydrochloride Injection (2ml:0.6g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Lincomycin Hydrochloride Injection is primarily used for patients who cannot use penicillin, treating severe infections caused by sensitive strains such as Streptococcus, Pneumococcus, and Staphylococcus [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 鹽酸林可霉素注射液（2ml:0.6g）主要用於不宜使用青霉素的患者，治療由鏈球菌、肺炎球菌 和葡萄球菌等敏感菌株引起的嚴重感染。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的鹽酸林可霉素注射液（2ml:0.6g）已取得中國國家藥品監督管理局批准通過仿製藥質 量和療效一致性評價。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年十一月三日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 ...